High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement (Q35750326)

10 August 2017

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement (English)

1 reference

10 August 2017

1 reference

7

David Dingli

1 reference

10 August 2017

3

Angela Dispenzieri

1 reference

10 August 2017

4

Martha Q Lacy

1 reference

10 August 2017

8

S Vincent Rajkumar

1 reference

10 August 2017

12

Morie A Gertz

1 reference

10 August 2017

5

Suzanne R Hayman

1 reference

10 August 2017

6

Francis K Buadi

1 reference

10 August 2017

2

Shaji K Kumar

1 reference

10 August 2017

11

Martha Grogan

1 reference

10 August 2017

Sumit Madan

1

1 reference

10 August 2017

William J Hogan

series ordinal

9

1 reference

10 August 2017

Nelson Leung

series ordinal

10

1 reference

10 August 2017

language of work or name

English

0 references

publication date

6 December 2011

1 reference

10 August 2017

1 reference

10 August 2017

119

1 reference

10 August 2017

5

1 reference

10 August 2017

1117-1122

1 reference

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Amyloidosis: is a cure possible?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Clinical aspects of systemic amyloid diseases.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Stem cell transplantation for the management of primary systemic amyloidosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

AL amyloidosis: the last 30 years

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL).

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3277349

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

25 September 2018

1 reference

12 December 2020

The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement

1 reference

12 December 2020

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate

1 reference

12 December 2020

Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response

1 reference

12 December 2020

Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report

1 reference

12 December 2020

10.1182/BLOOD-2011-07-370031

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

1 reference